Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
10:17am, Tuesday, 21'st Oct 2025
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys
11:16am, Monday, 20'th Oct 2025
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
12:04pm, Saturday, 18'th Oct 2025
Recent market speculation linking Johnson & Johnson NYSE: JNJ to a complete acquisition of its partner, Protagonist Therapeutics NASDAQ: PTGX, offers a valuable glimpse into a core corporate strategy
Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?
01:15pm, Friday, 17'th Oct 2025
JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.
S&P 500 Gains and Losses Today: Regional Banks Slump on Worries About Bad Loans; Data Storage Stocks Surge
05:45pm, Thursday, 16'th Oct 2025
Reports of elevated loan losses from regional banks weighed on the sector, while expectations of AI-driven growth helped lift shares of companies in the data storage and memory chip businesses.
J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
02:06pm, Thursday, 16'th Oct 2025
J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.
Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase
11:14am, Thursday, 16'th Oct 2025
Jamison Private Wealth Management, Inc. disclosed a purchase of Johnson & Johnson shares valued at $6,762,412 in its SEC filing for the period ended Q3 2025, submitted on October 14, 2025.
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook
09:56am, Thursday, 16'th Oct 2025
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
06:45am, Thursday, 16'th Oct 2025
The idea of steady money flowing in, year after year, should appeal to nearly everyone. This isn't an unrealistic dream; investing in stocks that pay reliable dividends can make it a reality.
Johnson & Johnson faces UK lawsuit over talcum baby powder
04:21am, Thursday, 16'th Oct 2025
A group of around 3,000 people in the UK has filed a legal claim against Johnson & Johnson (NYSE:JNJ), accusing the pharmaceutical company of selling...
Johnson & Johnson faces UK lawsuit over talcum baby powder
03:23am, Thursday, 16'th Oct 2025
A group of around 3,000 people in the UK has filed a legal claim against Johnson & Johnson (NYSE:JNJ), accusing the pharmaceutical company of selling talcum-based baby powder contaminated with asbesto
J&J faces first UK lawsuits alleging its baby powder caused cancer
07:03pm, Wednesday, 15'th Oct 2025
Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.
Markets Mostly Up, Russell 2000 Sets New Closing High
06:51pm, Wednesday, 15'th Oct 2025
The biggest movers on the day were the Nasdaq, +148 points or +0.66%, and the small-cap Russell 2000 +24 points, +0.97%.
